Takeaway

• 4 weeks of neoadjuvant immunotherapy led to major pathologic response (10% or less residual viable tumour) in 95% of patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, including 67% pathologic complete response ( no residual viable tumour in both the primary tumour bed and lymph nodes ).
• Neoadjuvant immunotherapy...